Publications by authors named "James F Demarest"

Claim this Profile
S
Small molecule direct-acting antivirals for treatment of mpox.
E Randall Lanier, Richard L Mackman, Lee Ruggiero, James F Demarest, John C Pottage

Antiviral Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness.
Ruxandra Draghia-Akli, Nina M Hill, Bruce Altevogt, Kenneth Bradley, Kelly Chibale, James F Demarest

Clin Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral target compound profile for pandemic preparedness.
James F Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A T Young

Nat Rev Drug Discov· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
James F Demarest, Maryline Kienle, RuthMabel Boytz, Mary Ayres, Eun Jung Kim

Antiviral Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Galidesivir in a Hamster Model of SARS-CoV-2.
Ray Taylor, Richard Bowen, James F Demarest, Michael DeSpirito, Airn Hartwig

Viruses· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
Justin G Julander, James F Demarest, Ray Taylor, Brian B Gowen, Dennis M Walling

Antiviral Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliable genotypic tropism tests for the major HIV-1 subtypes.
Kieran Cashin, Lachlan R Gray, Katherine L Harvey, Danielle Perez-Bercoff, Guinevere Q Lee, James F Demarest

Sci Rep· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Luke C Swenson, Celia K S Chui, Chanson J Brumme, Dennison Chan, Conan K Woods, James F Demarest

Antimicrob Agents Chemother· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
Jennifer M Pfaff, Craig B Wilen, Jessamina E Harrison, James F Demarest, Benhur Lee

J Virol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
John C Tilton, Heather Amrine-Madsen, John L Miamidian, Kathryn M Kitrinos, Jennifer Pfaff, James F Demarest

AIDS Res Hum Retroviruses· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
James F Demarest, Heather Amrine-Madsen, David M Irlbeck, Kathryn M Kitrinos,

Antimicrob Agents Chemother· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.
Kathryn M Kitrinos, Heather Amrine-Madsen, David M Irlbeck, J Michael Word, James F Demarest

Antimicrob Agents Chemother· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
James F Demarest, Sara S Sparks, Kathleen Schell, Shiro Shibayama, Charlene B McDanal

J Clin Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
David M Irlbeck, Heather Amrine-Madsen, Kathryn M Kitrinos, Celia C Labranche, James F Demarest

AIDS· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
Annika C Karlsson, Steven G Deeks, Jason D Barbour, Brandon D Heiken, Sophie R Younger, James F Demarest

J Virol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis